Results 281 to 290 of about 510,672 (398)

Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia.
Titiaan E. Post   +4 more
wiley   +1 more source

Techniques characterizing the coronary atherosclerotic plaque: influence on clinical decision making?

open access: bronze, 2000
Gerard Pasterkamp   +3 more
openalex   +1 more source

Prevalence of cardiac dysfunction in men with erectile dysfunction: the EDcard study

open access: yesBJU International, EarlyView.
Objectives To assess the prevalence of myocardial impairment in men with erectile dysfunction (ED) as compared with the general population using conventional and two‐dimensional speckle‐tracking echocardiography. Subjects and Methods In this cross‐sectional study, men with ED underwent clinical, electrocardiographic, and transthoracic echocardiographic
Emil Durukan   +11 more
wiley   +1 more source

Late‐onset multiple system atrophy: Neuropathological features associated with slow disease progression

open access: yesBrain Pathology, EarlyView.
Late‐onset multiple system atrophy (LO‐MSA; onset ≥75 years) shows milder degeneration of the striatonigral and olivopontocerebellar systems and serotonergic neurons in the ventrolateral medulla than usual‐age‐onset MSA with a similar disease duration. LO‐MSA may therefore exhibit slower pathological progression.
Misato Ozawa   +13 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

ADAMTS4-Specific MR Peptide Probe for the Assessment of Atherosclerotic Plaque Burden in a Mouse Model. [PDF]

open access: yesInvest Radiol
Mangarova DB   +16 more
europepmc   +1 more source

Site‐specific m6A‐miR‐494‐3p, not unmethylated miR‐494‐3p, compromises blood brain barrier by targeting tight junction protein 1 in intracranial atherosclerosis

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Intracranial atherosclerosis is one of the most common causes of ischaemic stroke. However, there is a substantial knowledge gap on the development of intracranial atherosclerosis. Intracranial arteries are characterized by an upregulation of tight junctions between endothelial cells, which control endothelial permeability.
Tamar Woudenberg   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy